For this position, University College London (UCL) is the recruiting organisation. You will be employed by UCL and embedded in the POLARIS consortium. Your academic supervision and disease-specific expertise will be provided by Professor Ahad A. Rahim (UCL School of Pharmacy), Professor Stephen Hart and Dr Julien Baruteau (UCL Great Ormond Street Institute of Child Health).

Keywords

#Lipid nanoparticles (LNPs) · #mRNA delivery · #Genetic therapies · #Leukodystrophies · #Preclinical mouse models

University College London

  • UK

You will work at University College London (UCL), within the UCL School of Pharmacy and the UCL Great Ormond Street Institute of Child Health.

UCL is ranked among the world’s leading universities. The UCL School of Pharmacy is part of the Faculty of Life Sciences and has 180 years of experience in research and education. The School is internationally recognised for its research in pharmacy and pharmacology.

Professor Rahim’s laboratory has extensive experience in genetic therapies and nucleic acid delivery technologies for rare paediatric neurodegenerative diseases. At the UCL Great Ormond Street Institute of Child Health, researchers work closely with Great Ormond Street Hospital. The institute is one of Europe’s largest centres for children’s health research. Professor Hart specialises in non-viral nucleic acid delivery systems, while Dr Baruteau combines clinical expertise with translational research.

PhD project description

This doctoral project focuses on the in vitro and in vivo preclinical assessment of genetic therapies for leukodystrophies. You will investigate lipid nanoparticle (LNP)-based approaches for delivering therapeutic nucleic acids, such as mRNA, in cellular and animal models.

The research follows a translational pathway towards clinical application. You will investigate the functionality, biodistribution and cellular tropism of LNP-mRNA delivery systems and evaluate their therapeutic efficacy in mouse models of leukodystrophies.

A planned secondment at the University of York will provide experience of working with patient-family organisations and exposure to additional disease models.

Eligibility criteria

Important, strict eligibility criteria according to MARIE SKLODOWSKA CURIE programs apply to applicants:

  1. You must not already hold a doctoral degree.
  2. At the time of the application deadline, you must have a Master’s degree and must not have resided or carried out your main activity (work, studies, etc.) in the UK for more than 12 months in the three years prior to the contract start date.
  3. You will participate in the network-wide training programme of POLARIS, which includes (international) training activities and planned secondments with POLARIS partner organizations throughout the EU.

Requirements and candidate profile

We are looking for a candidate with a Master’s degree in life sciences and relevant research experience gained through internships, thesis work or research projects.

You have experience with molecular technologies, neuroscience and in vivo mouse studies, as well as a strong interest in translational neuroscience, rare disease research and the development of genetic therapies. Experience with lipid nanoparticles (LNPs) and animal models of neurological disease would be considered an advantage.

You work accurately and reproducibly, with strong attention to detail and the ability to plan and organise complex experimental work effectively. In addition, you have good analytical, communication and collaboration skills and are able to work successfully in an interdisciplinary and international research environment.

Terms of employment

  • A contract for a total of 3 years;
  • Salary, mobility allowance and benefits according to the applicable MSCA Doctoral Network and host-organisation rules. More detailed information about the salary will follow;
  • Embedding in the international POLARIS doctoral training network;
  • Access to network-wide training activities, secondments and transferable-skills development;
  • A challenging and translational research project at the interface of in vivo neuroscience, rare disease biology and preclinical genetic therapy development;
  • A collaborative and entrepreneurial working environment;
  • An open and supportive team culture with opportunities for scientific and professional development.

Recruitment procedure and application

Applications for the doctoral positions have now closed. The selection process is currently ongoing, and applications are being reviewed by the recruiting institutions.

POLARIS is now moving into the next phase of its doctoral programme, which will bring together a new cohort of researchers working across disciplines and sectors to advance translational research in leukodystrophies.